Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Tot Biopharm Completes $66.5 Million Hong Kong IPO

publication date: Nov 7, 2019

Suzhou's Tot Biopharm completed a $66.5 million IPO on the Hong Kong Exchange to support development of its novel and biosimilar cancer drugs. Tot's portfolio consists of seven biological and five chemical candidates, all but one of them developed in-house. Its products include mAbs, antibody drug conjugates (ADCs), oncolytic virus products and specialty oncology drugs such as liposome drugs. Tot's lead product is an Avastin biosimilar that is expected to launch in late 2020 or early 2021. More details....

Stock Symbol: (HK: 1875)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.